ribociclib in 1st line hr+ breast cancer treatment
Clicks: 148
ID: 149227
2018
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
142 views
9 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Breast cancer is a leading oncologic disease among women worldwide. Though the achieved results in treating patients with luminal subtypes are high, there is a great demand on new approaches in this field. This article highlights the new CDK4/6 inhibitor ribociclib as well as presents clinical cases from the own clinical practice obtained during phase IIIb COMPLEEMENT trial.
| Reference Key |
zhukova2018ribociclib
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;L G Zhukova;I P Ganshina;O O Gordeeva;E V Lubennikova |
| Journal | acta histochemica supplementband |
| Year | 2018 |
| DOI |
10.26442/1815-1434_2018.2.38-41
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.